Vivus drug meets the target

Vivus drug meets the targetVivus Inc, a well known drugs company has announced that a second phase revision of its erectile dysfunction medicine congregated the key target of advancement of erectile function score by the two dosages that were experimented.

The experiment, called REVIVE-Diabetes (TA-302) has observed the security and usefulness of the drug avanafil in 390 male adults suffering from diseases like diabetes and erectile dysfunction.

The experiment exhibited considerable progress in erectile function and good quality intercourse within 15 minutes and past six hours after dosage intake. Last November, statistics from the first phase experiment called REVIVE (TA-301) on the drug exhibited that it met the core target and was helpful for 30 minutes or less than that.

Frequently reported adverse effects consist of head-pain, flushing, nasopharyngitis sinus congestion, dyspepsia and sinusitis. There were no drug-related severe undesirable proceedings in the experiment.

The corporation is performing 2 more tests on avanafil, in men who have undergone fundamental prostatectomy and an open-tag protection test. In totality, the late-phase avanafil experimental program will register about 1,300 patients and this experiment will target the patients with severe dysfunction, Vivus announced.